Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Phantom, I was considering what will constitute "good news"? I guess we will hear objective response rates and complete response rates (if any) or tumor shrinkage size.

Someone correct me if I am wrong on this (I'm not a medical anything), but first I was thinking, well, as long as there will still be no cytokine release syndrome and as long as we still get epitope spreading, that will be good news.....but then I thought, why would those 2 things not be almost automatic to happen.

I say that because if they are using the same 5 antigens for PC that they are using for AML, why would cytokine or epitope be any different results?

I don't think it should matter as far as what cancer is being targeted if its the same 5 antigens.
I could see if it were a different antigen cocktail because then "that antigen mix" might not produce epitope spreading, but if the 5 mix promotes epitope spreading in an AML patient, why wouldn't the same 5 mix do the same with a PC patient?
And the same logic for cytokine release?